Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Press release - No 11 / 2018
Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018
Copenhagen, 2 May, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will be presenting at the Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a late stage clinical portfolio of proprietary product candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
